Key facts
- This page summarizes Ph.D. Alan J. Main's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2025, 16:32.
Ph.D. Alan J. Main - 28 Feb 2025 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- EVP, Innov & Chem Sciences
- Issuer ticker
- LXRX
- Reported as of
- 28 Feb 2025
- Net transaction value
- -$29,101
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2025, 16:32:25 UTC
- Prior SEC filing
- 18 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alan J. Main, Ph.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Alan J. Main filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 03 Mar 2025.
Change
- Previous filing in this sequence was filed on 18 Feb 2025.
- Current net transaction value: -$29,101.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +25,667
- Change %
- +10%
- Price
- Shares after
- 281,391
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +32,904
- Change %
- +12%
- Price
- Shares after
- 314,295
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +68,243
- Change %
- +22%
- Price
- Shares after
- 382,538
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Tax liability
- Transaction value
- $29,101
- Shares
- -43,434
- Change %
- -11%
- Price
- $0.6700
- Shares after
- 339,104
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -25,667
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,667
- Exercise price
- Footnotes
- F1, F3
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -32,904
- Change %
- -50%
- Price
- Shares after
- 32,903
- Date
- 28 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,904
- Exercise price
- Footnotes
- F1, F3
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -68,243
- Change %
- -33%
- Price
- Shares after
- 136,487
- Date
- 28 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 68,243
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F2
Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
Footnote F3
Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.